Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.35 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.33 |
| ▸ | GOT1 | P17174 | 1/20 | 0.31 |
| ▸ | VNN1 | O95497 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15259719 | 0.75 | HRH4 (0.47) | KDM4EALDH1A1KAT2B | |
| SCHEMBL30401900 | 0.74 | ALDH1A1 (0.49) | KDM4EALDH1A1 | |
| SCHEMBL13983037 | 0.74 | ALDH1A1 (0.49) | KDM4EALDH1A1 | |
| SCHEMBL13734835 | 0.71 | KDM4E (0.37) | KDM4EALDH1A1 | |
| SCHEMBL3076036 | 0.69 | CYP1A2 (0.47) | ALDH1A1CYP1A2CTDSP1GOT1VNN1 | |
| SCHEMBL3079246 | 0.69 | CYP1A2 (0.47) | CYP1A2CTDSP1GOT1VNN1P2RX7 | |
| SCHEMBL13734841 | 0.69 | ALDH1A1 (0.43) | KDM4EALDH1A1 | |
| SCHEMBL20417166 | 0.69 | HRH4 (0.41) | KDM4EALDH1A1KAT2B | |
| SCHEMBL24915610 | 0.68 | KDM4E (0.40) | KDM4EALDH1A1 | |
| SCHEMBL17768583 | 0.68 | HRH4 (0.40) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9187486-B2 | Bicyclic pyridazine compounds as Pim inhibitors | AMGEN INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-20140221344-A1 | Bicyclic Pyridazine Compounds as PIM Inhibitors | AMGEN INC. | 2014-08-07 | — | — | US | disclosed |
| EP-2702063-A1 | BICYCLIC PYRIDAZINE COMPOUNDS AS PIM INHIBITORS | Amgen Inc. (US) | 2014-03-05 | — | — | EP | disclosed |
| WO-2012148775-A1 | BICYCLIC PYRIDAZINE COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2012-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221344-A1 | Bicyclic Pyridazine Compounds as PIM Inhibitors | PIM1, PIM2, PIM3 | KDM4E 743/4885ALDH1A1 719/4885CYP1A2 627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.